Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16017348 | 0.95 | TRPV1 (0.47) | SMN1; SMN2TRPV1KMT2AP2RY1S1PR3 | |
| SCHEMBL16019814 | 0.92 | S1PR3 (0.48) | TRPV1KMT2AP2RY1S1PR3 | |
| SCHEMBL14887510 | 0.88 | TLR8 (0.48) | TRPV1KMT2A | |
| SCHEMBL16017388 | 0.87 | SMN1; SMN2 (0.47) | LMNAHTTSMN1; SMN2KMT2AS1PR3 | |
| SCHEMBL14887509 | 0.87 | S1PR3 (0.52) | TRPV1KMT2AP2RY1S1PR3 | |
| SCHEMBL16017369 | 0.86 | SMN1; SMN2 (0.47) | LMNAHTTSMN1; SMN2KMT2AS1PR3 | |
| SCHEMBL16019807 | 0.85 | KMT2A (0.46) | TRPV1KMT2AP2RY1S1PR3 | |
| SCHEMBL16017370 | 0.85 | KMT2A (0.46) | TRPV1KMT2AS1PR3 | |
| SCHEMBL16017366 | 0.85 | LMNA (0.47) | LMNAHTTSMN1; SMN2P2RY1S1PR3 | |
| SCHEMBL16017360 | 0.85 | KMT2A (0.47) | TRPV1KMT2AP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256771-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256771-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | LMNA 1306/4885HTT 809/4885SMN1; SMN2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.